Asia-Pacific Infection Surveillance Solutions Market is Expected to Record the Highest Growth, 2023

Infection Surveillance Solutions MarketInfection is the invasion and multiplication of microorganisms such as viruses, bacteria and parasites that are not normally present within the human body. An infection may cause no symptoms and be hidden, or it may cause symptoms and be clinically visible. An infection may remain localized, or it may spread through the blood or lymphatic vessels to become systemic (present in the entire body). The global infection surveillance solutions market is growing due to the emergence of diseases caused by microorganisms that were previously not known. The microorganisms living naturally within the body are not considered as infectious for example, bacteria that normally live within the mouth and intestine such as E. coli do not cause an infection to the body. Hospital associated infections such as urinary tract infection, surgical site infections and pneumonia are increasing due to the use of contaminated devices, patient clothing, and other materials used in hospitals and clinics. This has thus provoked healthcare professionals and hospitals to adopt infection surveillance solutions to identify possible infections during the time the patient remains in hospital, and to develop necessary preventive measures for the same. These infection surveillance solutions also aid in diagnosing antibiotic resistant organisms (AROs) and infections due to non-sterile medical devices.

Explore Report at:

The infection surveillance solutions market is segmented on the basis of product and end user. The products are sub categorized into software and services. The software used for infection surveillance solutions are on-premise and cloud based software. The services include product support & maintenance, training & consultancy and implementation services. These surveillance solutions include usage of algorithms with specialized data mining software, electronic medical records and fully automated healthcare acquired infection (HAI) surveillance by employing clinical support based knowledge, that helps in identification of certain clinical terms. Several developments in infection surveillance solutions is making it simpler for healthcare staff to better understand surveillance software and its usage, which results in creating a trained workforce in the healthcare industry.

Explore Report Sample at:

The growth in the global infection surveillance solutions market is expected to be mainly due to the increasing incidence of HAIs; policies introduced by government for preventing these HAIs; and increase in expenditure in healthcare sector. According to World Health Organization (WHO), 9.9% of the gross domestic product (GDP) of the world was spent on healthcare in 2014. Furthermore, cost-effectiveness, and redundancy of clinical data and the increase in number of surgeries drive the growth of infection surveillance solutions market.

Some of the other key players in global market are, Premier Inc., Baxter International Inc., Gojo Industries, Inc., Truven Health Analytics (An IBM Company), DEB Group Ltd., Hygreen, Inc., Atlas Medical Software, and RL Solutions.


Radiation Dose Management – Industry Analysis, Size and Trends, 2023

Radiation Dose Management

Radiation dose refers to the total amount of ionizing radiation absorbed by the tissues. Humans are exposed to the ionizing radiation through natural sources such as soil, water, and sun and other human made sources such as X-ray machines and other medical devices. The effect of the radiation depends on the dose of the radiation absorbed by the tissues in the body. The radiation can impair the functioning of the organs and tissues beyond a certain threshold, and can lead to acute impacts such as hair loss, acute radiation syndrome, radiation burns, and skin redness. High radiation dose can also give rise to severe other health issues effects such as cancer in human beings. Global radiation dose management market is expected to witness significant growth in the forecast period (2017-2023), due to increasing concerns with respect to excess exposure to radiation.

Explore Report at:

On the basis of products and services, the global radiation dose management market is segmented into solutions and services. The solution segment held the largest share in the global market in 2016, and is expected to grow significantly in the forecast period. The growth is attributed to the compliance attained by integrating radiation dose monitoring, tracking, and analytics software with other systems such as RIS, PACS, and EHR to track, monitor and archive the dose information of patients and upgrade the safety of the patients.

Global radiation dose management market is expected to grow significantly during the forecast period (2017-2023). The major factors driving the growth of the global market include, increasing burden of radiation exposure, regulatory requirements, increasing emphasis on enhancing quality of patient care, and industry initiative to increase awareness on radiation dose management.

Explore Report Sample at:

In March 2017, The Connecticut Hospital Association (CHA) and Bayer AG announced an alliance to establish the U.S. first-ever statewide radiation dose management repository system for patients undergoing certain radiological procedures. The repository used Bayer AG’s Radimetrics, a radiation and contrast dose management and analytics tool that provides clinicians with data needed for them to help ensure that their patients receive the lowest necessary radiation dosage.

Medical Device Connectivity Market – Trends, Analysis and Growth, 2023

Medical Device Connectivity Market

The global medical device connectivity market is witnessing considerable growth due to increasing implementation of electronic health records and health information exchange systems, increasing regulations for improving healthcare quality, growing demand for home healthcare due to increasing geriatric population, improved diagnosis of patient, and increasing healthcare IT initiatives. Moreover, increasing prevalence of chronic diseases, increasing emphasis on care quality and patient safety, and increasing need to reduce healthcare costs through a connected healthcare environment are supporting the demand of medical device connectivity. The medical device connectivity aids in data analytics and growing adoption of telehealth solutions are also driving the growth of the market. Based on product type, the market for service segment is expected to grow at the faster rate compared to solution during the forecast period, due to increasing requirement for maximum consumption of connectivity solutions by the user, increasing regulatory requirements and healthcare reforms, increasing implementation of healthcare information exchange system, and increasing need for effective implementation.

Explore Report at:

The increasing demand for remote patient monitoring and telehealth, and increasing alliance in the healthcare industry are expected to create opportunities for the players in the market. In addition, immense unexplored market in developing economies are creating abundant opportunities for the medical device connectivity market to grow at a significant rate in the coming years. However, high cost of implementation for medical device connectivity platform in small healthcare organizations, lack of integration between various hospital information systems and medical devices, lack of standard interface, interoperability issues, security concerns, cost barrier for small healthcare units, and risk of data breaches are the key factors hampering the growth of the global market.

Explore Report Sample at:

The key players operating in the global medical device connectivity market are GE Healthcare, Cerner Corporation, Cisco Systems Inc., Qualcomm Inc., Koninklijke Philips N.V., Medtronic Plc., Infosys Limited, and Digi International Inc.

IgA Nephropathy – Pipeline Analysis, Clinical Trials & Results, 2017

IgA Nephropathy Pipeline

The study analyzed that the IgA nephropathy pipeline comprises of 12 drug candidates in different stages of development. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood. IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria and hematuria. IgA nephropathy does not have a specific treatment, and the only treatment available is to delay or prevent end stage renal disease (ESRD). Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.

Pharmalink AB is using TARGIT drug delivery technology platform for the development of Budesonide for IgA nephropathy. The TARGIT technology is based on the application of a combination of enteric polymers onto injection-moulded starch capsules, for the targeted delivery of drugs to specific regions of the large intestine.

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc. and others.

News Courtesy : P&S Market Research

Glaucoma Therapeutics Market – Research Report, Analysis, 2023

Glaucoma Therapeutics MarketOcular hypertension is one of the major causes due to which glaucoma occurs in patients. Glaucoma mostly occurs at the age over 40, but it may also occur in children, young adults, and infants. Diagnosis of glaucoma can be done through a simple eye examination with the help of tonometry, an instrument used for measuring intraocular pressure, by an ophthalmologists and optometrist. Prevention of glaucoma is difficult; however, if diagnosed and treated at an early stage, the disease can be controlled by using eye drops prescribed by doctor, microsurgery or by laser surgery. Glaucoma can damage the vision of the affected eye permanently; in first stage it decreases the peripheral vision and if not treated, it can lead to blindness.

For more information visit:

The global glaucoma therapeutics market can be divided into two types based on the factor that the disease is known or not. A known disease called as open angle and the not known disease is closed angle glaucoma.  Open angle glaucoma is painless and tends to develop slowly over time, with no symptoms until the disease progress to a considerable extent. Whereas, closed angle glaucoma is characterized by redness in eye, sudden eye pain, vomiting and various other symptoms and it should be treated immediately. On the basis of treatment used to cure the disease, the global glaucoma therapeutics market can be categorized as beta blockers, prostaglandins, carbonic anhydrase inhibitors, alpha adrenergic agonists, and fixed dose combinations.

Increase in awareness of glaucoma, medicare coverage of glaucoma patients and demand for combination glaucoma drugs are some of the major trends that can be seen in global glaucoma therapeutics market.

Explore Report Sample at:

Some of the major competitors in global glaucoma therapeutics market are Pfizer Inc., Allergen Inc., Novartis A.G., Merck & Co. Inc., Aerie Pharmaceuticals Inc., Inotek Pharmaceuticals Corp., Carl Zeiss Meditec Inc., Acadia Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., NicOx SA, Santen Pharmaceuticals Co. Ltd., Otsuka Holdings Co. Ltd., SIFI SpA, and Valeant Pharmaceuticals International Inc.

Bioinformatics Market – Analysis, Size and Forecast till 2023

Bioinformatics MarketThe introduction and adoption of cloud computing and nanopore technology are expected to offer numerous opportunities in the global bioinformatics market. The nanopore technology has been projected for getting used in the study of crop science, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins and small molecules with a range of applications in personalized medicine, and scientific research.

To know more visit:

Bioinformatics is a discipline that deals with the retrieval, storage, processing, management and analysis of organic information through computational techniques. Bioinformatics plays an important role in drug innovation and improvement. The involvement of bioinformatics in storing, retrieving, analyzing and forming biological information helps in efficiently managing enormous database associated with drug innovation and development.

The global bioinformatics market can be broadly segmented on the basis of applications, products and services, sectors and geographies. On the basis of products & services the bioinformatics market can be broadly bifurcated into bioinformatics platforms, bioinformatics knowledge management tools and bioinformatics services. The bioinformatics knowledge management tools segment can be further divided into specialized tools and generalized tools. The bioinformatics platforms are further sub-divided into sequence alignment platforms, sequence analysis platforms, structural & functional analysis platforms and sequence manipulation platforms. The bioinformatics services segment is again segmented into database & management, sequencing services and data analysis.

Explore Report Sample at:

Some of the key competitors within the global bioinformatics market include Tripos, LP, Affymetrix, Inc, Agilent Technologies, Illumina, Inc., Helicos Biosciences Corporation, IBM Life Sciences, Thermo Fisher Scientific Inc, Rosetta Inpharmatics LLC, Celera and others.

Healthcare/Medical Simulation Market – Research Report, Size & Growth, 2023


Healthcare Simulation Market

The global healthcare/medical simulation market is growing significantly due to technological advancements and increasing demand for minimally invasive procedures. Massive unexplored healthcare/medical simulation market in emerging economies and lack of service providers are creating ample opportunities for the global healthcare/medical simulation market to grow at a considerable rate in the coming years. However, lack of adequate input data for medical simulation models is a major challenge in the global healthcare and medical simulation market. Medical simulation trains medical professionals to minimise errors during surgical procedures by using advanced techniques of simulation. The simulated animations help students to understand the complexity of medical procedures through computer-based virtual patients.

Explore Report at:

Adoption of medical simulation technology in hospitals and academic institutes worldwide in order to reduce the medical errors and improve patient safety is a trend in healthcare/medical simulation market. Deaths occurring due to medical mistakes are major concern across the globe. According to a report published in September 2013, in the Journal of Patient Safety, more than 440,000 people die every year due to preventable medical errors. Healthcare simulation may simulate critical medical conditions without any harm to patients; this in turn helps medical professionals to evaluate their practices and reduce their mistakes. Medical simulation is capable of reproducing critical events over and over again and hence, explores consequences of each error or mistake made.

Geographically, North America will be leading the global healthcare/medical simulation market in the coming years, due to technological advancements, high healthcare expenditure, and presence of a large number of hospitals and academic institutions. In addition, Patient Safety and Quality Improvement Act in the U.S. is also driving its market in North America region. Asia-Pacific is the fastest growing region in the global healthcare/medical simulation market. The major reasons for the fastest growth in the region are improving healthcare infrastructure and increasing demand for minimally invasive procedures.

Explore Report Sample at:

Some of the major players operating in the global healthcare/medical simulation market are Laerdal Medical As, 3D Systems, Inc., CAE, Inc., Kyoto Kagaku Co., Ltd., Limbs & Things, Ltd., Gaumard Scientific Company, Inc., Simulab Corporation, Surgical Science Sweden Ab, and Mentice Ab.

Pain Management Drugs Market Analysis, Growth and Forecast to 2023

Pain Management Drugs Market

The growing geriatric population and increasing demand of innovative and advanced pain relaxing medications around the world are the predominant growth drivers for the global pain management drugs market. Additionally, the increasing number of hospitalization cases; unmet requirements for neuropathic pain management drugs; innovative and advanced applications of pain management therapies; increasing prevalence of various chronic diseases, such as cancer, and neurological problems; and increasing healthcare expenditure are also driving the growth of the global market. The growing numbers of mergers and acquisitions is a key trend observed in the market. Among the various therapeutic indications, the post-operative pain relief segment accounted for the largest share, and the low-back pain segment accounted for the second largest share in the global market.

Explore Report at:

Pain management drugs are mainly used to relieve discomfort associated with injury and surgeries. Moreover, pain management medications are used in the management of pain associated with neurological problems, migraine, cancer, orthopedic problems, low- back pain, rheumatoid arthritis, and fibromyalgia.

North America and Europe are the major markets, due to increasing prevalence of chronic diseases, and growing awareness about various types of chronic pain conditions in these regions. The U.S. followed by Canada, is the largest market for pain management drugs in North America. Whereas, the U.K., Germany and France are some of the major countries holding significant share in the European pain management drugs market.

Request for Table of Content at:

The Asian market is growing with a significant rate, owing to huge pool of patients, and increasing healthcare spending in the region. In addition, the initiatives taken by various government associations to develop chronic pain rehabilitation centers, and increasing prevalence of various chronic diseases are also supporting the growth of the Asian pain management drugs market. The countries such as India, Japan and China, are the major markets in the region.

Some of the major players operating in the global pain management drugs market include Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Forest Laboratories Inc., Endo International PLC, Johnson & Johnson, Pfizer Inc., Valeant Pharmaceuticals International Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., and Baxter International Inc.

Graft Versus Host Disease Treatment Market Pipeline Analysis, Growth and Forecast to 2023

Graft Versus Host Disease Treatment MarketThe global graft versus host disease (GVHD) treatment market is expected to witness considerable growth due to increasing number of hematopoietic stem cell transplantations (HSCTs), advancement in technologies, and increasing collaboration among the pharmaceutical companies. The regulatory bodies are supporting the graft versus host disease market by providing designations and grants for speeding up the drug development process. Currently, there are more than 15 targets, which are being used for the treatment of GVHD including T lymphocytes, OX40, Bruton’s tyrosine kinase, Toll-like receptors, tumor necrosis factor alpha, neutrophil elastase, and several B and T lymphocytes. Some of the companies use their own technologies for the development of drugs for graft versus host disease such as Bellicum Pharmaceuticals, Inc. and Targazyme, Inc.  Bellicum Pharmaceuticals, Inc. is using CaspaCIDe technology and Targazyme, Inc. is using Fucosylation technology.

Explore Report at:

The pipeline of GVHD is very rich with more than 60 drugs. Top pharmaceutical companies such as Dr. Falk Pharma GmbH and Mallinckrodt plc are expected to launch their products in coming years, as the products are in Phase III stage of development. The therapeutics involved in the treatment of GVHD comprise different molecule types including antibody drug conjugate, antibodies, cell therapy, monoclonal antibodies and recombinant proteins.

Geographically, North America was the largest market for GVHD treatment in 2015, owing to the high incidence of HSCTs, high healthcare expenditure and large number of research and development activities. The U.S. contributed largest revenue to the North American GVHD treatment market and it is expected to remain the largest market globally, during the forecast period.

Request for Table of Content at:

Some of the key players operating in the global market are Dr. Falk Pharma GmbH, Mallinckrodt Pharmaceuticals, Apceth GmbH & Co. KG, Targazyme Inc., Bellicum Pharmaceuticals, Inc., Cellect Biotechnology Ltd., Sanofi, Novartis AG, Gilead Sciences, Inc., AbbVie Inc., and Takeda Pharmaceutical Company Ltd.